ArQule (ARQL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. TSLA
4. NVDA
5. USO
6. AWK
7. GNK
8. ARGX
9. PLUR
10. RKLB

Go back to ArQule (ARQL) Misses Q4 EPS by 1c, Revenues Beat; Offers FY19 EPS Guidance Above Consensus, FY19 Revenue Guidance Below Consensus

ArQule (ARQL) PT Raised to $8 at Oppenheimer

March 8, 2019 9:11 AM EST

Oppenheimer analyst Hartaj Singh raised the price target on ArQule (NASDAQ: ARQL) to $8.00 (from $7.00) while maintaining a Outperform rating following the company's 4Q report. Results were in line with Oppenheimer's estimates and expectations. Singh has updated the model for 2019, with estimates in line with... More

Needham & Company Reiterates Bullish View on ArQule (ARQL) as Partial Response Seen in C481S Mutant Patient with ARQ-531

March 7, 2019 1:44 PM EST

Needham & Company analyst Chad Messer reiterated a Buy rating and $7 price target on ArQule (NASDAQ: ARQL) after a partial response was observed in ibrutinib refractory C481S mutant patient with ARQ-531.

"ArQule reported that the first patient treated in the current 7th... More

ArQule (ARQL) Surges 40% Following Results, Update

March 7, 2019 9:27 AM EST

ArQule (NASDAQ: ARQL) is gaining 40% in pre-open trade following results and update.

... More